Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TerrAscendTSNDF -3.99%38 Cash-to-Debt is 0.17 as of Jun. 2026, which is 6% below its 10-year median of 0.18. GuruFocus rates TSNDF with a GF Score™ of 38/100 and a GF Value™ of $0.77 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 979 Drug Manufacturers companies, TerrAscend ranks worse than 79.26% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. TerrAscend's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.17.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, TerrAscendcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for TerrAscend's Cash-to-Debt or its related term are showing as below:
TSNDF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09 Med: 0.18 Max: No Debt
Current: 0.17
During the past 10 years, TerrAscend's highest Cash to Debt Ratio was No Debt. The lowest was 0.09. And the median was 0.18.
TSNDF's Cash-to-Debt is ranked worse than 79.26% of 979
companies
in the Drug Manufacturers industry
Industry Median: 0.97
vs TSNDF: 0.17
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
TerrAscend Cash-to-Debt Related Terms
TerrAscend Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for TerrAscend's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, TerrAscend's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TerrAscend Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TerrAscend's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where TerrAscend's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TerrAscend (TSNDF) has a Cash-to-Debt of 0.17 as of Jun. 2026. This is near median its historical median of 0.18. Over the past decade, TerrAscend's Cash-to-Debt has ranged from 0.09 to 10,000.00. According to the industry distribution chart, TerrAscend ranks #776 out of 979 companies in the Drug Manufacturers industry, placing it in the top 79.3%.
Is TerrAscend's Cash-to-Debt too high?
TerrAscend's current Cash-to-Debt of 0.17 is near median its 10-year median of 0.18. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 10,000.00. The Drug Manufacturers industry median Cash-to-Debt is 0.97. TerrAscend's value of 0.17 is 82.5% below this industry median. Based on the distribution chart, TerrAscend ranks #776 out of 979 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, TerrAscend has a GF Score™ of 38/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TerrAscend's Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TerrAscend ranks #776 out of 979 companies for Cash-to-Debt. This places TerrAscend in the lower half of its industry. The industry median Cash-to-Debt is 0.97. TerrAscend's value of 0.17 is 82.5% below this benchmark. Historically, TerrAscend's own Cash-to-Debt has ranged from 0.09 to 10,000.00 over the past decade. While the company's 10-year median is 0.18 vs. the industry median of 0.97, TerrAscend has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.97, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TerrAscend's current Cash-to-Debt of 0.17 is 82.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TerrAscend's current Cash-to-Debt is 0.17, which is near median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TerrAscend stock overvalued right now?
Based on GuruFocus' analysis, TerrAscend (TSNDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.77, compared to a current price of $0.65 — trading 15.6% below its estimated fair value. The current Cash-to-Debt is 0.17, which is near median its 10-year median of 0.18 and 82.5% below the Drug Manufacturers industry median of 0.97. TerrAscend's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For TerrAscend (TSNDF), the current Cash-to-Debt is 0.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TerrAscend (TSNDF) Overvalued in 2026?
Based on GuruFocus' analysis, TerrAscend stock appears to be undervalued.
The current stock price of $0.65 is trading 15.6% below its estimated GF Value™ of $0.77.
GuruFocus considers TerrAscend to be Modestly Undervalued.
Key valuation signals for TSNDF:
Cash-to-Debt: 0.17 (near median its 10-year median of 0.18)
GF Value™: $0.77 vs. price of $0.65 (15.6% below fair value)
Industry Position: 82.5% below the Drug Manufacturers median (#776 of 979)
No single metric tells the full story. See the TSNDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TerrAscend Corp is a company focused on creating and delivering cannabis products and services that meet the evolving needs of its patients. It also provides education and support programs to physicians and patients through healthcare professionals. In addition, the firm operates in California, Maryland, New Jersey, and Pennsylvania, with retail operations in Ohio and Canada. It operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. The firm has one operating segment, being the cultivation, production, and sale of cannabis products, with subsidiaries located in Canada and the United States. The company generates key revenue from the United States.
38GF Score
Get the complete analysis for TSNDF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNDF has been successfully added to your 
